Divalproex sodium
Depakote, Divalproex (divalproex sodium) is a small molecule pharmaceutical. Divalproex sodium was first approved as Depakote on 1983-03-10. It is used to treat absence epilepsy, bipolar disorder, complex partial epilepsy, epilepsy, and epilepsy amongst others in the USA. It is known to target histone deacetylase 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
| mental disorders | D001523 |
Trade Name
FDA
EMA
Depakote (generic drugs available since 2008-07-29, discontinued: Depakote cp)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| depakote | New Drug Application | 2023-09-27 |
| depakote er | 2008-04-07 | |
| divalproex sodium | ANDA | 2024-01-18 |
| divalproex sodium delayed-release | 2008-12-04 | |
| divalproex sodium er | ANDA | 2023-04-03 |
| divalproex sodium extended-release | NDA authorized generic | 2015-01-03 |
| divalproex sodiumdelayed-release | ANDA | 2013-12-30 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
308 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 5 | 5 | 22 | 30 | 7 | 68 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 7 | 2 | 3 | 7 | 9 | 27 |
| Healthy volunteers/patients | — | — | — | 17 | — | — | 3 | — | 20 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 2 | 1 | 2 | 5 | 2 | 12 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 3 | 3 | 1 | 1 | 7 |
| Dementia | D003704 | EFO_0003862 | F03 | 1 | — | 2 | 2 | — | 5 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | 1 | 1 | 2 | — | 5 |
| Autistic disorder | D001321 | HP_0000717 | F84.0 | — | 3 | 1 | 1 | — | 5 |
| Glioma | D005910 | EFO_0000520 | — | 1 | 2 | — | 1 | — | 4 |
| Mania | D000087122 | — | F30 | — | — | — | 4 | — | 4 |
Show 26 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Seizures | D012640 | HP_0002069 | G40.4 | 1 | — | 3 | — | 2 | 6 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | 1 | 5 | — | — | 6 |
| Glioblastoma | D005909 | EFO_0000515 | — | 2 | 2 | 1 | — | — | 5 |
| Status epilepticus | D013226 | EFO_0008526 | G41 | — | 2 | 1 | — | 2 | 5 |
| Spinal muscular atrophy | D009134 | EFO_0003823 | G12.1 | 1 | 2 | 1 | — | — | 4 |
| Astrocytoma | D001254 | EFO_0000271 | — | 1 | 1 | 1 | — | — | 3 |
| Diffuse intrinsic pontine glioma | D000080443 | — | — | — | 1 | 1 | — | — | 2 |
| Neuroepithelial neoplasms | D018302 | — | — | — | 1 | 1 | — | — | 2 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | 1 | — | — | 2 |
| Uterine cervical neoplasms | D002583 | HP_0030159 | — | — | 1 | 1 | — | — | 2 |
Show 16 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 13 | 2 | — | — | — | 14 |
| Myelodysplastic syndromes | D009190 | — | D46 | 2 | 8 | — | — | — | 9 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 4 | 8 | — | — | — | 9 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 3 | 2 | — | — | 1 | 5 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 3 | 3 | — | — | — | 5 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 3 | 1 | — | — | — | 4 |
| Leukemia | D007938 | — | C95 | 1 | 3 | — | — | — | 3 |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | 2 | — | — | 1 | 3 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | 1 | — | — | — | 2 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 2 | 1 | — | — | — | 2 |
Show 40 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sarcoma | D012509 | — | — | 3 | — | — | — | 1 | 4 |
| Drug interactions | D004347 | — | — | 3 | — | — | — | — | 3 |
| Nasopharyngeal carcinoma | D000077274 | — | — | 2 | — | — | — | — | 2 |
| Nasopharyngeal neoplasms | D009303 | — | — | 2 | — | — | — | — | 2 |
| Central nervous system neoplasms | D016543 | — | — | 2 | — | — | — | — | 2 |
| Traumatic brain injuries | D000070642 | — | S06 | 1 | — | — | — | 1 | 2 |
| Hemorrhagic shock | D012771 | — | — | 2 | — | — | — | — | 2 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 1 | — | — | — | — | 1 |
| Burkitt lymphoma | D002051 | — | C83.7 | 1 | — | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
Show 21 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | — | — | 1 | 1 |
| Metabolic bone diseases | D001851 | HP_0000938 | — | — | — | — | — | 1 | 1 |
| Osteoporosis | D010024 | HP_0000939 | M81.0 | — | — | — | — | 1 | 1 |
| Insulin resistance | D007333 | HP_0000855 | E88.819 | — | — | — | — | 1 | 1 |
| Body composition | D001823 | — | — | — | — | — | — | 1 | 1 |
| Alveolar bone loss | D016301 | — | — | — | — | — | — | 1 | 1 |
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | — | — | — | — | 1 | 1 |
| Nocturnal enuresis | D053206 | — | N39.44 | — | — | — | — | 1 | 1 |
| Borderline personality disorder | D001883 | HP_0012076 | F60.3 | — | — | — | — | 1 | 1 |
| Cluster headache | D003027 | HP_0012199 | G44.00 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Divalproex sodium |
| INN | valproate semisodium |
| Description | Valproic acid is a branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem. It has a role as an anticonvulsant, a GABA agent, an EC 3.5.1.98 (histone deacetylase) inhibitor, a teratogenic agent, a psychotropic drug, a neuroprotective agent and an antimanic drug. It is a branched-chain saturated fatty acid and a branched-chain fatty acid. It is functionally related to a valeric acid. It is a conjugate acid of a valproate. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCC(CCC)C(=O)O.CCCC(CCC)C(=O)[O-].[Na+] |
Identifiers
| PDB | — |
| CAS-ID | 76584-70-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2105613 |
| ChEBI ID | 4667 |
| PubChem CID | 3121 |
| DrugBank | DB00510 |
| UNII ID | 644VL95AO6 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
HDAC1
HDAC1
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,923 documents
View more details
Safety
Black-box Warning
Black-box warning for: Depakote, Depakote er, Divalproex sodium, Divalproex sodium delayed-release, Divalproex sodium er, Divalproex sodium extended-release, Divalproex sodiumdelayed-release
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
17,416 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use